UAB Pharma Nord Lithuania Finance - revenue, profit
EBITDA margin (%)
Register and
explore Okredo dataEBIT margin (%)
Register and
explore Okredo data| Indicator |
|---|
| Turnover (€) |
| Sales per employee (€) |
| Profit before tax (€) |
| Net Profit (€) |
| Profit per employee (€) |
| Total profitability (%) |
| Net profitability (%) |
| Equity (€) |
| Amounts Payable And Liabilities (€) |
| Non-current Assets (€) |
| CurrentAssets (€) |
| Working capital requirement |
| Debt-to-equity ratio |
| EBITDA margin (%) |
| EBITDA (€) |
| EBIT margin (%) |
| EBIT (€) |
| 2022 |
|---|
| 266,104 |
| 45,488 |
| 13,305 |
| 13,109 |
| 2,241 |
| 5.89 |
| 4.93 |
| 17,502 |
| 73,022 |
| 0 |
| 90,524 |
| 0.33 |
| 4.17 |
| - |
| - |
| 5.89 |
| 15,662 |
| 2023 |
|---|
| 352,698 |
| 80,341 |
| 28,184 |
| 22,308 |
| 5,082 |
| 9.02 |
| 6.32 |
| 39,810 |
| 91,754 |
| 8,081 |
| 122,858 |
| 0.30 |
| 2.30 |
| - |
| - |
| 9.26 |
| 32,670 |
| 2024 |
|---|
| 550,179 |
| 110,036 |
| 25,920 |
| 22,751 |
| 4,550 |
| 5.73 |
| 4.14 |
| 26,561 |
| 536,177 |
| 6,716 |
| 510,767 |
| -0.05 |
| 20.19 |
| - |
| - |
| 5.67 |
| 31,209 |
| 2024 |
|---|
| 550,179 |
| 110,036 |
| 25,920 |
| 22,751 |
| 4,550 |
| 5.73 |
| 4.14 |
| 26,561 |
| 536,177 |
| 6,716 |
| 510,767 |
| -0.05 |
| 20.19 |
| - |
| - |
| 5.67 |
| 31,209 |
Turnover (€)
2024
Turnover (€)
550,179 €56 % *
Sales per employee (€)
110,036 €37 % *
Profit before tax (€)
25,920 €-8 % *
Net Profit (€)
22,751 €2 % *
Profit per employee (€)
4,550 €-10 % *
Total profitability (%)
5.73 %-36.47 % *
Net profitability (%)
4.14 %-34.49 % *
Equity (€)
26,561 €-33 % *
Amounts Payable And Liabilities (€)
536,177 €484 % *
Non-current Assets (€)
6,716 €-17 % *
CurrentAssets (€)
510,767 €316 % *
Working capital requirement
-0.05 -116.67 % *
Debt-to-equity ratio
20.19 777.83 % *
EBITDA margin (%)
-EBITDA (€)
-EBIT margin (%)
5.67 %-38.77 % *
EBIT (€)
31,209 €-4 % *
